(Q27852105)

English

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

1 reference

based on heuristic

inferred from title

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis (English)

1 reference

13 November 2016

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Shuangjie Wu

1

0 references

Yu Gan

2

0 references

Xinhai Wang

3

0 references

Jun Liu

4

0 references

Mengjun Li

5

0 references

Yifan Tang

6

0 references

publication date

May 2013

0 references

Journal of Cancer Research and Clinical Oncology

0 references

139

0 references

5

0 references

891-900

0 references

https://scigraph.springernature.com/pub.10.1007/s00432-013-1400-x

0 references

End points in advanced colon cancer clinical trials: a review and proposal

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

The continuum of care: a paradigm for the management of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Functional analysis of PIK3CA gene mutations in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1400-X

21 January 2018

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-013-1400-X

0 references

Dimensions Publication ID

0 references

1 reference

13 November 2016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852105&oldid=1949913515"